Skip to main content

Table 1 Inhibitory effect of MBIC against human cancerous and non-cancer cell-lines

From: Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell

Cell line MBIC Colchicine Nocodazole Paclitaxel Doxorubicin Cisplatin
  IC50 SI IC50 SI IC50 SI IC50 SI IC50 SI IC50 SI
IC50 (μM)/24 hours
  HeLa 0.21 ± 0.02 48.04 3.01 ± 0.03 2.66 3.08 ± 0.02 3.97 1.02 ± 0.01 6.57 0.46 ± 0.04 7.73 15.07 ± 0.03 1.23
  HCT-116 2.72 ± 0.4 3.70 5.34 ± 0.2 1.50 3.81 ± 0.6 3.20 3.09 ± 0.5 2.17 0.91 ± 0.2 3.91 7.22 ± 0.5 2.57
  A549 1.29 ± 0.07 7.82 7.78 ± 0.3 1.03 12.16 ± 0.2 1.00 2.83 ± 0.11 2.37 0.35 ± 0.07 10.17 34.04 ± 0.9 0.54
  HepG-2 2.92 ± 0.1 3.45 8.36 ± 0.9 0.95 10.71 ± 0.5 1.14 2.81 ± 0.72 2.38 8.04 ± 0.8 0.44 10.31 ± 0.5 1.80
  WRL-68 10.09 ± 1.2   8.02 ± 0.5   12.23 ± 0.9   6.71 ± 0.2   3.56 ± 0.9   18.6 ± 1.4  
IC50 (μM)/48 hours
  HeLa 0.19 ± 0.03 37.68 2.02 ± 0.02 2.04 2.22 ± 0.04 3.40 0.57 ± 0.03 5.98 0.29 ± 0.04 5.79 9.02 ± 0.02 1.17
  HCT-116 2.01 ± 0.3 3.56 3.44 ± 0.2 1.20 1.81 ± 0.3 4.17 1.09 ± 0.4 3.12 0.47 ± 0.3 3.57 4.12 ± 0.6 2.56
  A549 0.53 ± 0.1 13.50 3.21 ± 0.7 1.28 5.09 ± 0.5 1.48 1.23 ± 0.09 2.77 0.09 ± 0.01 18.66 19.51 ± 1.4 0.54
  HepG-2 1.03 ± 0.09 6.95 4.08 ± 0.4 1.01 5.08 ± 0.3 1.48 1.03 ± 0.07 3.31 3.94 ± 0.07 0.42 5.93 ± 0.2 1.78
  WRL-68 7.16 ± 0.9   4.14 ± 0.7   7.56 ± 0.3   3.41 ± 0.8   1.68 ± 0.09   10.56 ± 0.7  
  1. Human cervical cancer (HeLa), colorectal (HCT-116), lung cancer (A549), hepatocellular (HepG-2) cell-lines and human embryonic normal liver cell line (WRL-68) were treated with DMSO as vehicle control, various concentration of MBIC and selected conventional drugs (colchicine, nocodazole, paclitaxel, doxorubicin and cisplatin) for 24 and 48 h. Cell viability was determined by MTT assay and by calculation of half maximal inhibitory concentration (IC50). Data were mean ± SD of three independent experiments. (P < 0.05). Selectivity Index (SI) is calculated by dividing IC50 of non-cancer cell-line (WRL-68) against IC50 of human cancer cell-lines